Country: Կանադա
language: անգլերեն
source: Health Canada
CALCIUM GLUCONATE
BAXTER CORPORATION
B05XA19
CALCIUM GLUCONATE
100MG
SOLUTION
CALCIUM GLUCONATE 100MG
INTRAVENOUS
15G/50G
Ethical
Active ingredient group (AIG) number: 0108566002; AHFS:
APPROVED
2021-12-08
Calcium Gluconate Injection, USP 10% - Prescribing Information Page 1 of 9 PRESCRIBING INFORMATION CALCIUM GLUCONATE INJECTION, USP 10% Solution, 100 mg / mL (0.446 mEq / mL) For Intravenous Use Pharmacy bulk package: 50 000 mg per 500 mL ATC Code: B05BB01 Electrolyte Replenisher BAXTER CORPORATION 7125 Mississauga Road Mississauga, ON L5N 0C2 Date of Preparation: December 8, 2021 Submission Control No: 242725 Baxter and Clearflex are trademarks of Baxter International Inc. Calcium Gluconate Injection, USP 10% - Prescribing Information Page 2 of 9 TABLE OF CONTENTS 1. INDICATIONS ............................................................................................................. 3 2. CONTRAINDICATIONS ............................................................................................. 3 3. DOSAGE AND ADMINISTRATION........................................................................... 3 3.1 Recommended Dose and Dosage Adjustment..........................................................3 3.2 Administration .......................................................................................................4 3.3 Reconstitution ........................................................................................................5 4. OVERDOSAGE ............................................................................................................ 5 5. DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ................. 5 6. WARNINGS AND PRECAUTIONS ............................................................................ 6 6.1 Special Populations ................................................................................................7 6.1.1 Pregnant Women....................................................................................................7 6.1.2 Breast-feeding........................................................................................................7 7. ADVERSE REACTIONS .............................................................................. read_full_document